Literature DB >> 24551307

Systemic mastocytosis with associated myeloproliferative neoplasm with t(8;19)(p12;q13.1) and abnormality of FGFR1: report of a unique case.

Christina B Duckworth1, Linsheng Zhang1, Shiyong Li1.   

Abstract

Systemic mastocytosis is a neoplastic proliferation of mast cells that frequently presents with associated clonal hematological non-mast cell lineage disease. Myeloid and lymphoid neoplasms with abnormalities of the FGFR1 gene are a heterogenous group of rare and aggressive hematopoietic stem cell disorders. About a dozen of chromosome changes involving the FGFR1 gene, presenting as myeloid or lymphoid neoplasms, have been described in the literature. To date, only 2 cases of myeloid and lymphoid neoplasms with abnormalities of the FGFR1 gene have been reported in association with systemic mastocytosis, one with t(8;13) and one with t(8;17) involving the FGFR1 gene. Here we describe another case of myeloproliferative neoplasm with chromosome translocation t(8;19) involving FGFR1 gene associated with systemic mastocytosis.

Entities:  

Keywords:  FGFR1; Myeloproliferative neoplasm; eosinophilia; systemic mastocytosis associated with clonal hematological non-mast cell lineage disease

Mesh:

Substances:

Year:  2014        PMID: 24551307      PMCID: PMC3925931     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  25 in total

1.  Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation.

Authors:  V Ollendorff; G Guasch; D Isnardon; R Galindo; D Birnbaum; M J Pébusque
Journal:  J Biol Chem       Date:  1999-09-17       Impact factor: 5.157

2.  Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).

Authors:  Géraldine Guasch; Cornel Popovici; Francine Mugneret; Max Chaffanet; Pierre Pontarotti; Daniel Birnbaum; Marie-Josèphe Pébusque
Journal:  Blood       Date:  2002-06-28       Impact factor: 22.113

3.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.

Authors:  Ken-Hong Lim; Ayalew Tefferi; Terra L Lasho; Christy Finke; Mrinal Patnaik; Joseph H Butterfield; Rebecca F McClure; Chin-Yang Li; Animesh Pardanani
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

4.  Cytogenetic response induced by interferon alpha in the myeloproliferative disorder with eosinophilia, T cell lymphoma and the chromosomal translocation t(8;13)(p11;q12)

Authors:  J A Martinez-Climent; E Vizcarra; I Benet; I Marugan; M J Terol; C Solano; C Arbona; M Tormo; A M Comes; J García-Conde
Journal:  Leukemia       Date:  1998-06       Impact factor: 11.528

5.  FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33).

Authors:  G Guasch; G J Mack; C Popovici; N Dastugue; D Birnbaum; J B Rattner; M J Pébusque
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

6.  8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.

Authors:  G Guasch; V Ollendorff; J P Borg; D Birnbaum; M J Pébusque
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

7.  Mast cell disease followed by leukemia with clonal evolution.

Authors:  J P Lewis; J L Welborn; F J Meyers; N B Levy; T Roschak
Journal:  Leuk Res       Date:  1987       Impact factor: 3.156

8.  The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins.

Authors:  A Demiroglu; E J Steer; C Heath; K Taylor; M Bentley; S L Allen; P Koduru; J P Brody; G Hawson; R Rodwell; M L Doody; F Carnicero; A Reiter; J M Goldman; J V Melo; N C Cross
Journal:  Blood       Date:  2001-12-15       Impact factor: 22.113

9.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder.

Authors:  Jing Chen; Daniel J Deangelo; Jeffery L Kutok; Ifor R Williams; Benjamin H Lee; Martha Wadleigh; Nicole Duclos; Sarah Cohen; Jennifer Adelsperger; Rachel Okabe; Allison Coburn; Ilene Galinsky; Brian Huntly; Pamela S Cohen; Thomas Meyer; Doriano Fabbro; Johannes Roesel; Lolita Banerji; James D Griffin; Sheng Xiao; Jonathan A Fletcher; Richard M Stone; D Gary Gilliland
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-24       Impact factor: 11.205

Review 10.  Acute myeloid leukemia associated with FGFR1 abnormalities.

Authors:  Hyeyoung Lee; Myungshin Kim; Jihyang Lim; Yonggoo Kim; Kyungja Han; Byung-Sik Cho; Hee-Je Kim
Journal:  Int J Hematol       Date:  2013-04-23       Impact factor: 2.490

View more
  1 in total

Review 1.  Updates on eosinophilic disorders.

Authors:  Alexandar Tzankov; Kaaren K Reichard; Robert P Hasserjian; Daniel A Arber; Attilio Orazi; Sa A Wang
Journal:  Virchows Arch       Date:  2022-09-07       Impact factor: 4.535

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.